Abstract:Hydrolytic reactions constitute an important pathway of drug metabolism and a significant route of prodrug activation. Many ophthalmic drugs and prodrugs contain ester groups that greatly enhance their permeation across several hydrophobic barriers in the eye before the drugs are either metabolized or released, respectively, via hydrolysis. Thus, the development of ophthalmic drug therapy requires the thorough profiling of substrate specificities, activities, and expression levels of ocular esterases. However, such information is scant in the literature, especially for preclinical species often used in ophthalmology such as rabbits and pigs. Therefore, our aim was to generate systematic information on the activity and expression of carboxylesterases (CESs) and arylacetamide deacetylase (AADAC) in seven ocular tissue homogenates from these two species. The hydrolytic activities were measured using a generic esterase substrate (4-nitrophenyl acetate) and, in the absence of validated substrates for rabbit and pig enzymes, with selective substrates established for human CES1, CES2, and AADAC (d-luciferin methyl ester, fluorescein diacetate, procaine, and phenacetin). Kinetics and inhibition studies were conducted using these substrates and, again due to a lack of validated rabbit and pig CES inhibitors, with known inhibitors for the human enzymes. Protein expression levels were measured using quantitative targeted proteomics. Rabbit ocular tissues showed significant variability in the expression of CES1 (higher in cornea, lower in conjunctiva) and CES2 (higher in conjunctiva, lower in cornea) and a poor correlation of CES expression with hydrolytic activities. In contrast, pig tissues appear to express only CES1, and CES3 and AADAC seem to be either low or absent, respectively, in both species. The current study revealed remarkable species and tissue differences in ocular hydrolytic enzymes that can be taken into account in the design of esterase-dependent prodrugs and drug conjugates, the evaluation of ocular effects of systemic drugs, and in translational and toxicity studies.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c01154.Tables of chromatography gradient program data and MRM parameters for the analysis of CESs and AADAC peptides and figures of Michaelis–Menten kinetics of NPA, DME, and FDA hydrolysis, inhibition of NPA hydrolysis in pig cornea using general and human isoform-selective inhibitors, inhibition of DME hydrolysis by digitonin, inhibition of FDA hydrolysis by human CES2-selective inhibitors, and correlation between hydrolytic activities and CES isozyme contents in pig and rabbit ocular tissues (PDF)This article has not yet been cited by other publications.

Role of carboxylesterase and arylacetamide deacetylase in drug metabolism, physiology, and pathology

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

Protein Acylation is a General Regulatory Mechanism in Biosynthetic Pathway of Acyl-CoA-Derived Natural Products

Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans

Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review

Carboxylesterase inhibitors from clinically available medicines and their impact on drug metabolism

Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans

[Role of Human Orphan Esterases in Drug-induced Toxicity]

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators

Role of acid ceramidase in the degradation of N-acylethanolamines, a group of anti-inflammatory and anorexic lipid mediators

Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing

In Vitro Drug Metabolism by Human Carboxylesterase 1: Focus on Angiotensin-Converting Enzyme Inhibitors

Arylacetamide deacetylase regulates hepatic iron homeostasis to protect against carbon tetrachloride-induced ferroptosis

Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation

Elusive Roles of the Different Ceramidases in Human Health, Pathophysiology, and Tissue Regeneration

Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity

The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro

Contributions of Cathepsin A and Carboxylesterase 1 to the hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis

Carboxylesterase Activities and Protein Expression in Rabbit and Pig Ocular Tissues

Absorption, Distribution, Metabolism, and Excretion of FDA‐approved Antisense Oligonucleotide Drugs

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development